|
KMID : 0191120220370190159
|
|
Journal of Korean Medical Science
2022 Volume.37 No. 19 p.159 ~ p.159
|
|
|
Diagnostic Value of Anti-Nuclear Antibodies: Results From Korean University-Affiliated Hospitals
|
|
Kang Seong-Hun
Seo Young-Il
Lee Mi-Hyun
Kim Hyun-Ah
|
|
|
Abstract
|
|
|
Background: Unnecessary and inappropriate laboratory testing accounts for a significant portion of waste in health care utilization. The aim of this study was to examine the diagnostic value of the anti-nuclear antibody (ANA) test by examining the rate of ANA associated rheumatic disease (AARD) diagnosis among ANA tested and ANA positive subjects and positive predictive value (PPV) of ANA test leading to AARD diagnosis in different ANA titers and different subsets of patients in 5 hospitals affiliated with a university.
Methods: We retrospectively extracted data from all subjects who were tested for ANA from year 2010 to 2019. Those who were first evaluated at or referred to rheumatology were further evaluated with extraction of data including ANA titer and ultimate diagnosis. PPVs for ANA test were evaluated after stratification according to clinically relevant key parameters, such as patient age (younger < 65 years vs. older), sex, and requesting department.
Results: From 2010 to 2019, A total of 94,153 patients were tested for ANA, of which 13,600 (14.4% of the total) were positive. AARD was diagnosed in only 0.69% among all ANA tested patients and 4.74% among ANA positive patients. The AARD diagnosis rate of ANA positive patients varied widely from 0.1% to 8.7% by requesting department. Using cutoff values above 1:320 yielded PPVs of 15.6 and 7.8% for all AARs and systemic lupus erythematosus. The PPV was significantly higher in young age (< 65 years) and in women, and when it was requested from internal medicine vs other departments.
Conclusion: AARD was diagnosed in less than 1% of all ANA tested patients in university-affiliated hospitals. This result shows that careful consideration before ordering the screening ANA is needed to improve the utility of the test for providers and patients and to reduce health costs spurred by unnecessary testing and its consequences.
|
|
|
KEYWORD
|
|
|
Anti-Nuclear Antibody, Systemic Lupus Erythematosus, Autoimmunity, Health Care Costs
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|